138 related articles for article (PubMed ID: 26197800)
1. Ovarian-type epithelial tumours of the testis: immunohistochemical and molecular analysis of two serous borderline tumours of the testis.
Bürger T; Schildhaus HU; Inniger R; Hansen J; Mayer P; Schweyer S; Radzun HJ; Ströbel P; Bremmer F
Diagn Pathol; 2015 Jul; 10():118. PubMed ID: 26197800
[TBL] [Abstract][Full Text] [Related]
2. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.
Sieben NL; Macropoulos P; Roemen GM; Kolkman-Uljee SM; Jan Fleuren G; Houmadi R; Diss T; Warren B; Al Adnani M; De Goeij AP; Krausz T; Flanagan AM
J Pathol; 2004 Mar; 202(3):336-40. PubMed ID: 14991899
[TBL] [Abstract][Full Text] [Related]
3. Determination of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in borderline and low-grade ovarian cancers.
Sadlecki P; Walentowicz P; Bodnar M; Marszalek A; Grabiec M; Walentowicz-Sadlecka M
Tumour Biol; 2017 May; 39(5):1010428317706230. PubMed ID: 28488545
[TBL] [Abstract][Full Text] [Related]
4. The mutational frequency of BRAF and KRAS in low-grade serous testicular neoplasms-a case series.
Gwiti P; Vereczkey I; Cundell D; Aslam S; Clench T; Csernák E; Götzer K; Braybrooke J; Sohail M; Melegh Z
Histopathology; 2017 Nov; 71(5):686-692. PubMed ID: 28543997
[TBL] [Abstract][Full Text] [Related]
5. Serous borderline tumor of the paratestis: a report of seven cases.
McClure RF; Keeney GL; Sebo TJ; Cheville JC
Am J Surg Pathol; 2001 Mar; 25(3):373-8. PubMed ID: 11224608
[TBL] [Abstract][Full Text] [Related]
6. BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors.
Zeppernick F; Ardighieri L; Hannibal CG; Vang R; Junge J; Kjaer SK; Zhang R; Kurman RJ; Shih IeM
Am J Surg Pathol; 2014 Dec; 38(12):1603-11. PubMed ID: 25188864
[TBL] [Abstract][Full Text] [Related]
7. Intratesticular serous cystadenoma of borderline malignancy. A pathological, histochemical and DNA content study of a case with long-term follow-up.
De Nictolis M; Tommasoni S; Fabris G; Prat J
Virchows Arch A Pathol Anat Histopathol; 1993; 423(3):221-5. PubMed ID: 8236817
[TBL] [Abstract][Full Text] [Related]
8. Borderline serous papillary tumour of the testis: a case report and review of the literature.
Ibrahim AS; Li C; Al-Jafari MS
Anticancer Res; 2012 Nov; 32(11):5011-3. PubMed ID: 23155272
[TBL] [Abstract][Full Text] [Related]
9. Serous borderline tumor of the paratestis.
Maruyama H; Ohyama N; Hosokawa Y; Momose H; Yamada K; Tsutsumi M; Kuniyasu H; Enomoto Y; Uematsu K; Konishi Y
Pathol Int; 2008 May; 58(5):311-6. PubMed ID: 18429831
[TBL] [Abstract][Full Text] [Related]
10. Serous borderline tumours of the ovary.
Kurman RJ; Seidman JD; Shih IM
Histopathology; 2005 Sep; 47(3):310-5. PubMed ID: 16115232
[TBL] [Abstract][Full Text] [Related]
11. A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes.
Russell SE; McCluggage WG
J Pathol; 2004 Jun; 203(2):617-9. PubMed ID: 15141374
[TBL] [Abstract][Full Text] [Related]
12. Wilms tumor gene 1 (WT1), TP53, RAS/BRAF and KIT aberrations in testicular germ cell tumors.
Boublikova L; Bakardjieva-Mihaylova V; Skvarova Kramarzova K; Kuzilkova D; Dobiasova A; Fiser K; Stuchly J; Kotrova M; Buchler T; Dusek P; Grega M; Rosova B; Vernerova Z; Klezl P; Pesl M; Zachoval R; Krolupper M; Kubecova M; Stahalova V; Abrahamova J; Babjuk M; Kodet R; Trka J
Cancer Lett; 2016 Jul; 376(2):367-76. PubMed ID: 27085458
[TBL] [Abstract][Full Text] [Related]
13. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors.
Ho CL; Kurman RJ; Dehari R; Wang TL; Shih IeM
Cancer Res; 2004 Oct; 64(19):6915-8. PubMed ID: 15466181
[TBL] [Abstract][Full Text] [Related]
14. The V600E BRAF mutation in a borderline serous tumour of the testis is genotypic evidence of similarity with its phenotypic ovarian counterpart.
Cundell D; Pawade J; Sohail M; Melegh Z
Histopathology; 2015 Jul; 67(1):142-4. PubMed ID: 25491441
[No Abstract] [Full Text] [Related]
15. KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome.
Zuo T; Wong S; Buza N; Hui P
Mod Pathol; 2018 Feb; 31(2):350-357. PubMed ID: 29027536
[TBL] [Abstract][Full Text] [Related]
16. Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR.
Bösmüller H; Fischer A; Pham DL; Fehm T; Capper D; von Deimling A; Bonzheim I; Staebler A; Fend F
Hum Pathol; 2013 Mar; 44(3):329-35. PubMed ID: 23089489
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in ovarian serous borderline tumors.
Hayashi Y; Sasaki H; Takeshita S; Nishikawa R; Nishikawa H; Arakawa A; Yamashita Y; Takahashi S; Sugiura-Ogasawara M
Oncol Rep; 2014 Nov; 32(5):1815-9. PubMed ID: 25174456
[TBL] [Abstract][Full Text] [Related]
18. Mutations of BRAF and RAS are rare events in germ cell tumours.
Sommerer F; Hengge UR; Markwarth A; Vomschloss S; Stolzenburg JU; Wittekind C; Tannapfel A
Int J Cancer; 2005 Jan; 113(2):329-35. PubMed ID: 15386408
[TBL] [Abstract][Full Text] [Related]
19. Ovarian high-grade serous carcinoma with a noninvasive growth pattern simulating a serous borderline tumor.
Imamura H; Ohishi Y; Aman M; Shida K; Shinozaki T; Yasutake N; Sonoda K; Kato K; Oda Y
Hum Pathol; 2015 Oct; 46(10):1455-63. PubMed ID: 26232113
[TBL] [Abstract][Full Text] [Related]
20. Seromucinous borderline tumor of the testis-A case report.
Scholz B; Beckert M; Mordstein V; Hohmann N; Walther R; Papadopoulos T
Hum Pathol; 2017 Feb; 60():188-191. PubMed ID: 27597522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
